Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seeking Guidance On Abuse-Deterrence: Sponsors Fall Short, Congress Urges Action

This article was originally published in RPM Report

Executive Summary

Congressional appropriators are urging FDA to move quickly to finalize guidance on abuse deterrence claims for opioids—and to take the next step and prohibit marketing of products that don’t deter abuse. FDA says the science isn’t there yet, and two sponsors join the list of those who have failed to clear the hurdle.

Advertisement

Related Content

FDA Funding Helped By Ebola Emergency Spending, But Opioid Issue Still Rankles Appropriators
Pfizer Gets Abuse-Deterrent Claim on One Pain Drug, Then Drops Development of Another
FDA May Emerge From Zohydro Approval Purgatory in October
FDA Sticks To Hard Line On Abuse-Deterrent Opioids; Acura Takes A Hit
Pfizer’s Remoxy Clears Manufacturing Hurdle, Still Needs BE, Abuse-Potential Studies
The Best Bad Deal of All Time? Pfizer/King and the Business Dynamics of Abuse Deterrence
OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible
Controlling Opioids: REMS Meets Congressional Resistance

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel